InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

- Current share price for CUV : $8.160

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$411 Managing Director Address 17 Oct 2025 12:54PM $11.760 $8.160 fallen by 30.61%
$411 Chair address 17 Oct 2025 10:03AM $11.830 $8.160 fallen by 31.02%
$411 Health Canada requests additional time for SCENESSE review 16 Oct 2025 12:43PM $12.000 $8.160 fallen by 32%
$411 Section 708A Cleansing Statement 3 Oct 2025 8:55AM $12.110 $8.160 fallen by 32.62%
$411 Notification of cessation of securities - CUV 3 Oct 2025 8:53AM $12.110 $8.160 fallen by 32.62%
$411 Application for quotation of securities - CUV 3 Oct 2025 8:51AM $12.110 $8.160 fallen by 32.62%
$411 Application for quotation of securities - CUV 3 Oct 2025 8:47AM $12.110 $8.160 fallen by 32.62%
$411 Management update 1 Oct 2025 8:32AM $11.800 $8.160 fallen by 30.85%
$411 CLINUVEL advances new formulations in preclinical program 29 Sep 2025 8:36AM $11.300 $8.160 fallen by 27.79%
$411 EMA approves year-round SCENESSE treatment 23 Sep 2025 8:32AM $11.220 $8.160 fallen by 27.27%
$411 SCENESSE efficacy in vitiligo - new cases presented to EADV 19 Sep 2025 8:25AM $11.520 $8.160 fallen by 29.17%
$411 Becoming a substantial holder 17 Sep 2025 8:20AM $11.240 $8.160 fallen by 27.40%
$411 Notice of Annual General Meeting/Proxy Form 15 Sep 2025 8:28AM $10.600 $8.160 fallen by 23.02%
$411 Chair's Letter to Shareholders 5 Sep 2025 9:01AM $10.570 $8.160 fallen by 22.80%
$411 Date of Annual General Meeting 3 Sep 2025 9:15AM $10.430 $8.160 fallen by 21.76%
$411 CLINUVEL Annual Results - Investor Webinar 29 Aug 2025 9:08AM $12.530 $8.160 fallen by 34.88%
$411 Investor Presentation 28 Aug 2025 9:37AM $13.550 $8.160 fallen by 39.78%
$411 Corporate Governance Statement 28 Aug 2025 9:36AM $13.550 $8.160 fallen by 39.78%
$411 Appendix 4G 28 Aug 2025 9:36AM $13.550 $8.160 fallen by 39.78%
$411 Dividend/Distribution - CUV 28 Aug 2025 9:36AM $13.550 $8.160 fallen by 39.78%
$411 CLINUVEL delivers ninth consecutive revenues growth & profit 28 Aug 2025 9:35AM $13.550 $8.160 fallen by 39.78%
$411 Appendix 4E and Annual Report to Shareholders 2025 28 Aug 2025 9:34AM $13.550 $8.160 fallen by 39.78%
$411 CLINUVEL preparing upgrade of ADR program, NASDAQ uplist 22 Aug 2025 9:30AM $11.990 $8.160 fallen by 31.94%
$411 CLINUVEL Annual Results - Investor Webinar 21 Aug 2025 12:17PM $11.950 $8.160 fallen by 31.72%
$411 Bioshares Biotech Summit presentation 7 Aug 2025 9:24AM $12.280 $8.160 fallen by 33.55%

51 - 75 of 871 results

Page 3 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.